MedElevator
Войти в исследования Psychiatry research · 2026
Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mustonen Antti, Niemelä Solja, Denissoff Alexander, Forti Marta Di, Tanskanen Antti, Mittendorfer-Rutz Ellenor, Tiihonen Jari, Taipale Heidi
Аннотация
BACKGROUND: Cannabis-induced psychosis (CIP) carries a high risk of relapse. Research has shown that antipsychotic medications are effective in relapse prevention after first diagnosed CIP. Given that antipsychotics carry the potential for dose-related adverse effects, understanding the optimal dose is critical. Therefore, we conducted a dose-response analysis to evaluate the real-world effectiveness of oral antipsychotics in preventing relapse after CIP.
METHODS: We used data from linkage of administrative and health care registers from Sweden to identify all individuals with first diagnosis of CIP (ICD-10 F12.5). We modelled oral antipsychotic exposure (aripiprazole, clozapine, risperidone, olanzapine, quetiapine, antipsychotic polytherapy, other oral antipsychotics) as time-dependent using validated PRE2DUP-method. Dose-response association of antipsychotic exposure and outcome were examined across three predefined daily dose (DDD) categories (<0.6, 0.6-<1.4, ≥1.4) using within-individual models in a stratified Cox-regression analysis. The primary outcome was hospitalization for any psychotic episode, defined as schizophrenia-spectrum disorder (F20-F29) or substance-induced psychosis (F1x.5) as the main diagnosis.
RESULTS: We identified 1,772 individuals aged 16-64 years with first-time CIP between 2006 and 2021. Antipsychotic polytherapy was associated with reduced risk of psychosis hospitalization across all dose ranges (HRs=0.54-0.65). Clozapine (0.6-<1.4 DDDs/day), olanzapine (≥0.6 DDDs/day), aripiprazole (0.6-<1.4 DDDs/day), risperidone (<0.6 DDDs/day), and other oral antipsychotics (0.6-<1.4 DDDs/day) were effective, while quetiapine showed no significant benefit.
CONCLUSIONS: Findings indicate dose-dependent real-world effectiveness of antipsychotics in CIP, with most agents performing best at 0.6-<1.4 DDDs/day. These results support optimizing dosing of oral antipsychotic medications for relapse prevention after CIP to balance efficacy and adverse effects.
METHODS: We used data from linkage of administrative and health care registers from Sweden to identify all individuals with first diagnosis of CIP (ICD-10 F12.5). We modelled oral antipsychotic exposure (aripiprazole, clozapine, risperidone, olanzapine, quetiapine, antipsychotic polytherapy, other oral antipsychotics) as time-dependent using validated PRE2DUP-method. Dose-response association of antipsychotic exposure and outcome were examined across three predefined daily dose (DDD) categories (<0.6, 0.6-<1.4, ≥1.4) using within-individual models in a stratified Cox-regression analysis. The primary outcome was hospitalization for any psychotic episode, defined as schizophrenia-spectrum disorder (F20-F29) or substance-induced psychosis (F1x.5) as the main diagnosis.
RESULTS: We identified 1,772 individuals aged 16-64 years with first-time CIP between 2006 and 2021. Antipsychotic polytherapy was associated with reduced risk of psychosis hospitalization across all dose ranges (HRs=0.54-0.65). Clozapine (0.6-<1.4 DDDs/day), olanzapine (≥0.6 DDDs/day), aripiprazole (0.6-<1.4 DDDs/day), risperidone (<0.6 DDDs/day), and other oral antipsychotics (0.6-<1.4 DDDs/day) were effective, while quetiapine showed no significant benefit.
CONCLUSIONS: Findings indicate dose-dependent real-world effectiveness of antipsychotics in CIP, with most agents performing best at 0.6-<1.4 DDDs/day. These results support optimizing dosing of oral antipsychotic medications for relapse prevention after CIP to balance efficacy and adverse effects.